News from SGC

Posted on Monday 16th of May 2022

Toronto, May 16, 2022 – An article published today in the journal Nature Chemical Biology reveals a mechanism of antitumor activity for triple negative breast cancer, which is the most aggressive breast cancer subtype with less promising prognosis and with few effective therapies.

Posted on Tuesday 8th of March 2022

Toronto, March  8, 2022 - The Structural Genomics Consortium (SGC) is pleased to announce three new members of the open science consortium: Bristol Myers Squibb, Genentech, a member of the Roche Group, and Janssen Pharmaceutica NV.

Posted on Friday 25th of February 2022

Toronto, February 25, 2022 - The Structural Genomics Consortium (SGC) is excited to welcome the Montreal Neurological Institute-Hospital (The Neuro) at McGill University and Open Chemistry Networks (OCN) based at University College London (UCL) as its latest academic partners.

SGC is pleased to have The Neuro and UCL officially contribute to our academic network, adopting SGC’s “patent-free” open science model for their SGC-associated teams.

Posted on Tuesday 22nd of February 2022

 

Toronto, February 22, 2022 – The roadmap for CACHE, an open science benchmarking initiative to enable the development of computational methods for hit-finding, has been published in Nature Reviews Chemistry.

Posted on Monday 22nd of November 2021

Toronto, November 23, 2021 – The Structural Genomics Consortium (SGC) is pleased to announce a new research initiative, funded by The Michael J. Fox Foundation for Parkinson’s Research, focusing on the WD domain of LRRK2. Using computational methods, this initiative will explore complementary and novel therapeutic strategies to target LRRK2.

Posted on Thursday 11th of November 2021

Cyclica and Structural Genomics Consortium co-crystallize DCAF1, a key component in proteasomal degradation, with a novel ligand to support targeted therapeutics discovery

11 November, 2021

Toronto, Canada

Cyclica, the partner of choice for data-driven drug discovery, and the Structural Genomics Consortium (SGC), a global public-private partnership dedicated to open science, have collaborated on a project in support of Target 2035, an initiative to discover probe molecules in support of developing medicines for all.

Posted on Thursday 7th of October 2021

 

New look for Target 2035

SGC’s Target 2035 initiative just launched a new website with a fresh look and feel. Users will be able to access information about the project, upcoming webinars, and general updates. Check the Target 2035 Twitter and Linked In accounts for the latest news.

What is Target 2035

Posted on Friday 12th of February 2021

Inhibiting a key enzyme that controls a large network of proteins important in cell division and growth paves the way for a new class of drugs that could stop glioblastoma, a deadly brain cancer, from growing.

Researchers at Princess Margaret Cancer Centre, the Hospital for Sick Children (SickKids) and University of Toronto, showed that chemically inhibiting the enzyme PRMT5 can suppress the growth of glioblastoma cells.

Pages

Subscribe to News from SGC
glqxz9283 sfy39587stf02 mnesdcuix8
sfy39587stf03